Serviços Personalizados
Journal
Artigo
Espanhol (pdf)
Artigo em XML
Referências do artigo
Tradução automática
Enviar este artigo por emailIndicadores
Citado por SciELO 
Acessos
Links relacionados
Similares em
SciELO
Compartilhar
Permalink
Revista de sanidad militar
versão impressa ISSN 0301-696X
Resumo
MARTIN-HERNANDEZ, Patricia et al. Safety and experience of the use of hyperbaric oxygen in the patient with acute myocardial infarction with ST elevation. Rev. sanid. mil. [online]. 2018, vol.72, n.3-4, pp.231-239. ISSN 0301-696X.
Hyperbaric oxygen (HBO2) is a useful treatment for ischemic diseases; however, as an adjuvant treatment in myocardial infarction (MI), there is very little experience worldwide. It has been used in some research work as a single treatment in a single exposure in the context of an ST-segment elevation myocardial infarction (STEMI) and in addition to thrombolysis. Our study describes the feasibility and safety of continuous doses of HBO2 after a heart attack by improving left ventricular function.
Objective
The objective of this study is to describe the experience and safety of HBO2 doses in the patient with STEMI taken to primary angioplasty to improve left ventricular function.
Material and methods
24 randomized patients were collected and divided into two groups: 13 in the case group and 11 control patients. Both groups were taken to primary angioplasty and conventional treatment. Left ventricular function was assessed with SPECT CT; the case group received 15 repeated 90-minute sessions of isopressure at 2.0 ATA.
Results
The two groups were similar in characteristics; they were admitted to the hospital with an STEMI, taken to primary angioplasty, randomized into two groups. The group of cases was taken to the hyperbaric chamber to receive daily doses of HBO2 for 15 days at 2 ATA for 90 minutes of isopressure. There were no cardiovascular complications during the treatment with hyperbaric oxygen: reinfarction, bleeding, hypertensive disorder, arrhythmias or heart failure data. Complications typical of the hyperbaric chamber: only one patient presented significant claustrophobia. In addition to the benefits of the conventional treatment of STEMI, the left-ventricular ejection fraction (LVEF) in anteroseptal MI was significantly improved in the group of cases.
Conclusions
Continuous-dose hyperbaric oxygen is safe and feasible as an additional treatment for patients with STEMI taken to primary angioplasty, in addition to improving left ventricular function in extensive heart attacks.
Palavras-chave : Hyperbaric; infarction; myocardium; SPECT.
